Overview

CP-690-550 Ointment For Chronic Plaque Psoriasis

Status:
Completed
Trial end date:
2011-11-29
Target enrollment:
0
Participant gender:
All
Summary
The study is being conducted to see whether CP-690,550 ointment has potential as a safe and effective treatment for adult patients with mild to moderate chronic plaque psoriasis.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Tofacitinib
Criteria
Inclusion Criteria:

- Mild to moderate chronic plaque psoriasis (psoriasis vulgaris), with the duration of
at least 6 months;

- A target plaque of at least 9 sq. cm.

Exclusion Criteria:

- Demonstrates "rebound" or "flare" of chronic plaque psoriasis;

- Non plaque form of psoriasis;

- Currently have or history of psoriatic arthritis;

- Current drug induced psoriasis;

- Currently on systemic therapy or was on systemic therapy for psoriasis within the
previous 6 months;

- Currently on phototherapy for psoriasis or was on phototherapy within the previous 3
months